Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 2 |
Descriptor
Source
| Journal of the American… | 2 |
Author
| March, John | 2 |
| Silva, Susan | 2 |
| Vitiello, Benedetto | 2 |
| Casat, Charles | 1 |
| Emslie, Graham | 1 |
| Kratochvil, Christopher | 1 |
| Mayes, Taryn | 1 |
| McNulty, Steven | 1 |
| Pathak, Sanjeev | 1 |
| Posner, Kelly | 1 |
| Rohde, Paul | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkMarch, John; Silva, Susan; Vitiello, Benedetto – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Funded by the National Institute of Mental Health, the Treatment for Adolescents With Depression Study (TADS) is intended to evaluate the short-term (12 weeks) and longer-term (36 weeks) effectiveness of four treatments for adolescents with DSM-IV major depressive disorder: clinical management with fluoxetine (FLX), cognitive-behavioral therapy…
Descriptors: Patients, Adolescents, Public Health, Quality of Life
Emslie, Graham; Kratochvil, Christopher; Vitiello, Benedetto; Silva, Susan; Mayes, Taryn; McNulty, Steven; Weller, Elizabeth; Waslick, Bruce; Casat, Charles; Walkup, John; Pathak, Sanjeev; Rohde, Paul; Posner, Kelly; March, John – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To compare the rates of physical, psychiatric, and suicide-related events in adolescents with MDD treated with fluoxetine alone (FLX), cognitive-behavioral therapy (CBT), combination treatment (COMB), or placebo (PBO). Method: Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic…
Descriptors: Safety, Patients, Adolescents, Suicide
